Skip To Main Content
Joan How on Muck Rack

Joan How

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Joan How’s profile

Articles by Joan How

Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing - Leukemia

|
By Jonas S. Jutzi, Edie I. Crosse, Chulwoo Kim, Charles Laurore, Benjamin Rolles, Frederike Kramer, Azucena Rocha, Mohammed Wazir, Lachelle D. Weeks, Joan How, Maximilian Stahl, Marlise R. Luskin, R. Coleman Lindsley, Olga Pozdnyakova, Sumit Rai, Timothy A Graubert, Robert Bradley, Ann Mullally, Anna E. Marneth, Bob van Gasteren, Anastasia Tishena
| Nature Verified
Abstract Somatic mutations in RNA splicing regulators, including the serine/arginine-rich protein SRSF2, are frequently observed in myeloid malignancies. Using mouse models and primary human samples, we investigated the impact of SRSF2 mutations on erythropoiesis. We found reduced erythropoiesis in Srsf2P95H versus wild-type mice upon stress-induced erythropoiesis and identified that SRSF2 mutations correlate with reduced hemoglobin in JAK2-mutant patients with myeloproliferative neoplasms (MPN).
Open in Who Shared Issue with article?

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms - Leukemia

|
By Benjamin Rolles, Nathan Fergusson, Jan Philipp Bewersdorf, Julia M Keating, Cecelia Perkins, Matthew Schwede, James England, Marlise R. Luskin, Daniel DeAngelo, Shai Shimony, Mifra Faiz, Addison C. Hillerbrand, Chulwoo Kim, Lachelle D. Weeks, Lauren Waldman, Mohammed Wazir, Joan How, Anna E. Marneth, Yiwen Liu, Martin J. Aryee, Raajit Rampal, Harrison K. Tsai, Jason Gotlib, Vikas Gupta, Maximilian Stahl, Ann Mullally
| Nature Verified
Abstract While TP53 mutations in myeloproliferative neoplasms (MPN) are associated with an increased risk of leukemic transformation, not all patients carrying a TP53 mutation progress. To better risk-stratify MPN patients with TP53 mutations, we analyzed data from 1540 patients treated at four specialized cancer centers. Among them, 1429 had wildtype TP53 and 111 had mutations in the TP53 gene.
Open in Who Shared Issue with article?

Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera

|
By Maggie Allen, Stephen T. Oh, Jared S. Fowles, Joan How
| Nature Verified
Access optionsAccess options Subscribe to Journal Get full journal access for 1 year $1,224.00 only $102.00 per issue All prices are NET prices. VAT will be added later in the checkout. Rent or Buy article Get time limited or full article access on ReadCube. from$8.99 All prices are NET prices. Additional information Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References 1. Tefferi A, Pardanani A.
Open in Who Shared Issue with article?
Show More